IFN alpha-IFNAR-IN-1 (hydrochloride)

IFN alpha-IFNAR-IN-1 (hydrochloride)

• CAS Number: 2070014-98-9
• UNSPSC Description: IFN alpha-IFNAR-IN-1 hydrochloride is a nonpeptidic, low-molecular-weight inhibitor of the interaction between IFN-α and IFNAR. IFN alpha-IFNAR-IN-1 hydrochloride inhibits modified Vaccinia virus ankara (MVA)-induced IFN-α responses in murine bone-marrow-derived, Flt3- L-differentiated pDC cultures (BM-pDCs) (IC50=2-8 μM)[1].
• Target Antigen: IFNAR
• Type: Reference compound
• Related Pathways: Immunology/Inflammation
• Field of Research: Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/IFN-alpha-IFNAR-IN-1-hydrochloride.html
• Purity: 99.87
• Solubility: DMSO : 100 mg/mL (ultrasonic)|H2O : 16.67 mg/mL (ultrasonic)
• Smiles: CNCC1=CC=CC=C1SC2=C(C=CC=C3)C3=CC=C2.[H]Cl
• Molecular Weight: 315.86
• References & Citations: [1]Geppert T, et al. Immunosuppressive small molecule discovered by structure-based virtual screening for inhibitors of protein-protein interactions. Angew Chem Int Ed Engl. 2012 Jan 2;51(1):258-61.Adv Healthc Mater. 2023 Jan 30;e2202830.|Arthritis Res Ther. 2022 Jul 19;24(1):170.|Cell Death Dis. 2020 Dec 11;11(12):1050.|Cell Mol Life Sci. 2022 Jan 20;79(2):83.|Cell Rep. 2023 Feb 28;42(3):112145.|Cell Rep. 2024 Apr 23;43(4):114088.|Clin Exp Immunol. 2020 Dec 23.|Exp Eye Res. 2021 Jan;202:108375.|Front Immunol. 2019 Oct 11;10:2391.|J Med Virol. 2023 Nov 7.|Mol Oncol. 2023 Sep 25.|Nature. 2022 Sep;609(7928):785-792.|Pharmacol Res. 2022 Dec 16;187:106615.|PLoS Pathog. 2022 Feb 14;18(2):e1010301.|Viruses. 2022, 14(8), 1806.|Arthritis Rheumatol. 2020 Jun;72(6):1003-1012.|Cell Rep. 2022 Nov 29;41(9):111738.|Free Radic Biol Med. 10 October 2022.|Front Immunol. 2019 May 3;10:980.|Sci Rep. 2016 Jul 14;6:29665.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
• Clinical Information: No Development Reported